Muriel Boulton
Research Subjects
Muriel Boulton has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Anna Dari
Janssen Research & Development Beerse Belgium
3 shared publications - Juan Jose Perez Ruixo
Johnson & Johnson Madrid Spain
3 shared publications Mathieu Le Gars
Janssen Vaccines and Prevention Leiden The Netherlands
2 shared publications- Abishek Chandrashekar
Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA 02115, USA
1 shared publication - Belén Valenzuela
Janssen‐Cilag Spain Part of Janssen Pharmaceutical Companies Madrid Spain
1 shared publication - Dan H. Barouch
Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA
1 shared publication
Latest Publications
- 3 August 2023
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 387 (1) , 121-130
Mechanistic Model Describing the Time Course of Humoral Immunity Following Ad26.COV2.S Vaccination in Non-Human Primates
Mechanistic modeling can be used to describe the time course of vaccine-induced humoral immunity and to identify key biological drivers in antibody production. We utilized a six-compartment mechanistic model to describe a 20-week time course of humoral immune responses in 56 non-human primates (NHPs) elicited by vaccination with Ad26.COV2.S according to either a single-dose regimen (1 × 1011 or 5 × 1010 viral particles [vp]) or a two-dose homologous regimen (5 × 1010 vp) given in an interval of 4 or 8 weeks. Humoral immune responses were quantified by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike-specific binding antibody concentrations as determined by spike protein-enzyme-linked immunosorbent assay (S-ELISA). The mechanistic model adequately described the central tendency and variability of binding antibody concentrations through 20 weeks in all vaccination arms. The estimation of mechanistic modeling parameters revealed greater contribution of the antibody production mediated by short-lived cells as compared to long-lived cells in driving the peak response, especially post second dose when a more rapid peak response was observed. The antibody production mediated by long-lived cells was identified as relevant for generating the first peak and for contributing to the long-term time course of sustained antibody concentrations in all vaccination arms. The findings contribute evidence on the key biological components responsible for the observed time course of vaccine-induced humoral immunity in NHPs and constitute a step toward defining immune biomarkers of protection against SARS-CoV-2 that might translate across species. Significance Statement We demonstrate the adequacy of a mechanistic modeling approach describing the time course of binding antibody concentrations in non-human primates (NHPs) elicited by different dose levels and regimens of Ad26.COV2.S. The findings are relevant for informing the mechanism-based accounts of vaccine-induced humoral immunity in NHPs and translational research efforts aimed at identifying immune biomarkers of protection against SARS-CoV-2 infection.
- 3 August 2023
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 387 (1) , 121-130
Mechanistic Model Describing the Time Course of Humoral Immunity Following Ad26.COV2.S Vaccination in Non-Human Primates
Mechanistic modeling can be used to describe the time course of vaccine-induced humoral immunity and to identify key biological drivers in antibody production. We utilized a six-compartment mechanistic model to describe a 20-week time course of humoral immune responses in 56 non-human primates (NHPs) elicited by vaccination with Ad26.COV2.S according to either a single-dose regimen (1 × 1011 or 5 × 1010 viral particles [vp]) or a two-dose homologous regimen (5 × 1010 vp) given in an interval of 4 or 8 weeks. Humoral immune responses were quantified by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike-specific binding antibody concentrations as determined by spike protein-enzyme-linked immunosorbent assay (S-ELISA). The mechanistic model adequately described the central tendency and variability of binding antibody concentrations through 20 weeks in all vaccination arms. The estimation of mechanistic modeling parameters revealed greater contribution of the antibody production mediated by short-lived cells as compared to long-lived cells in driving the peak response, especially post second dose when a more rapid peak response was observed. The antibody production mediated by long-lived cells was identified as relevant for generating the first peak and for contributing to the long-term time course of sustained antibody concentrations in all vaccination arms. The findings contribute evidence on the key biological components responsible for the observed time course of vaccine-induced humoral immunity in NHPs and constitute a step toward defining immune biomarkers of protection against SARS-CoV-2 that might translate across species. Significance Statement We demonstrate the adequacy of a mechanistic modeling approach describing the time course of binding antibody concentrations in non-human primates (NHPs) elicited by different dose levels and regimens of Ad26.COV2.S. The findings are relevant for informing the mechanism-based accounts of vaccine-induced humoral immunity in NHPs and translational research efforts aimed at identifying immune biomarkers of protection against SARS-CoV-2 infection.
- Open Access
- 9 December 2022
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 113 (2) , 380-389
Quantifying Antibody Persistence After a Single Dose of COVID‐19 Vaccine Ad26.COV2.S in Humans Using a Mechanistic Modeling and Simulation Approach
Understanding persistence of humoral immune responses elicited by vaccination against coronavirus disease 2019 (COVID‐19) is critical for informing the duration of protection and appropriate booster timing. We developed a mechanistic model to characterize the time course of humoral immune responses in severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2)–seronegative adults after primary vaccination with the Janssen COVID‐19 vaccine, Ad26.COV2.S. The persistence of antibody responses was quantified through mechanistic modeling‐based simulations. Two biomarkers of humoral immune responses were examined: SARS‐CoV‐2 neutralizing antibodies determined by wild‐type virus neutralization assay (wtVNA) and spike protein‐binding antibodies determined by indirect spike protein enzyme‐linked immunosorbent assay (S‐ELISA). The persistence of antibody responses was defined as the period of time during which wtVNA and S‐ELISA titers remained above the lower limit of quantification. A total of 442 wtVNA and 1,185 S‐ELISA titers from 82 and 220 participants, respectively, were analyzed following administration of a single dose of Ad26.COV2.S (5 × 1010 viral particles). The mechanistic model adequately described the time course of observed wtVNA and S‐ELISA serum titers and its associated variability up to 8 months following vaccination. Mechanistic model‐based simulations show that single‐dose Ad26.COV2.S elicits durable but waning antibody responses up to 24 months following immunization. Of the estimated model parameters, the production rate of memory B cells was decreased in older adults relative to younger adults, and the antibody production rate mediated by long‐lived plasma cells was increased in women relative to men. A steeper waning of antibody responses was predicted in men and in older adults.
- 9 December 2022
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 113 (2) , 380-389
Open AccessQuantifying Antibody Persistence After a Single Dose of COVID‐19 Vaccine Ad26.COV2.S in Humans Using a Mechanistic Modeling and Simulation Approach
Understanding persistence of humoral immune responses elicited by vaccination against coronavirus disease 2019 (COVID‐19) is critical for informing the duration of protection and appropriate booster timing. We developed a mechanistic model to characterize the time course of humoral immune responses in severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2)–seronegative adults after primary vaccination with the Janssen COVID‐19 vaccine, Ad26.COV2.S. The persistence of antibody responses was quantified through mechanistic modeling‐based simulations. Two biomarkers of humoral immune responses were examined: SARS‐CoV‐2 neutralizing antibodies determined by wild‐type virus neutralization assay (wtVNA) and spike protein‐binding antibodies determined by indirect spike protein enzyme‐linked immunosorbent assay (S‐ELISA). The persistence of antibody responses was defined as the period of time during which wtVNA and S‐ELISA titers remained above the lower limit of quantification. A total of 442 wtVNA and 1,185 S‐ELISA titers from 82 and 220 participants, respectively, were analyzed following administration of a single dose of Ad26.COV2.S (5 × 1010 viral particles). The mechanistic model adequately described the time course of observed wtVNA and S‐ELISA serum titers and its associated variability up to 8 months following vaccination. Mechanistic model‐based simulations show that single‐dose Ad26.COV2.S elicits durable but waning antibody responses up to 24 months following immunization. Of the estimated model parameters, the production rate of memory B cells was decreased in older adults relative to younger adults, and the antibody production rate mediated by long‐lived plasma cells was increased in women relative to men. A steeper waning of antibody responses was predicted in men and in older adults.
- Open Access
- 7 October 2021
- Published by Springer Nature in Nature Communications
- Vol. 12 (1) , 1-10
SARS-CoV-2 binding and neutralizing antibody levels after Ad26.COV2.S vaccination predict durable protection in rhesus macaques
Several COVID-19 vaccines have recently gained authorization for emergency use. Limited knowledge on duration of immunity and efficacy of these vaccines is currently available. Data on other coronaviruses after natural infection suggest that immunity to SARS-CoV-2 might be short-lived, and preliminary evidence indicates waning antibody titers following SARS-CoV-2 infection. In this work, we model the relationship between immunogenicity and protective efficacy of a series of Ad26 vectors encoding stabilized variants of the SARS-CoV-2 Spike protein in rhesus macaques and validate the analyses by challenging macaques 6 months after immunization with the Ad26.COV2.S vaccine candidate that has been selected for clinical development. We show that Ad26.COV2.S confers durable protection against replication of SARS-CoV-2 in the lungs that is predicted by the levels of Spike-binding and neutralizing antibodies, indicating that Ad26.COV2.S could confer durable protection in humans and immunological correlates of protection may enable the prediction of durability of protection.
- 7 October 2021
- Published by Springer Nature in Nature Communications
- Vol. 12 (1) , 1-10
Open AccessSARS-CoV-2 binding and neutralizing antibody levels after Ad26.COV2.S vaccination predict durable protection in rhesus macaques
Several COVID-19 vaccines have recently gained authorization for emergency use. Limited knowledge on duration of immunity and efficacy of these vaccines is currently available. Data on other coronaviruses after natural infection suggest that immunity to SARS-CoV-2 might be short-lived, and preliminary evidence indicates waning antibody titers following SARS-CoV-2 infection. In this work, we model the relationship between immunogenicity and protective efficacy of a series of Ad26 vectors encoding stabilized variants of the SARS-CoV-2 Spike protein in rhesus macaques and validate the analyses by challenging macaques 6 months after immunization with the Ad26.COV2.S vaccine candidate that has been selected for clinical development. We show that Ad26.COV2.S confers durable protection against replication of SARS-CoV-2 in the lungs that is predicted by the levels of Spike-binding and neutralizing antibodies, indicating that Ad26.COV2.S could confer durable protection in humans and immunological correlates of protection may enable the prediction of durability of protection.